Bedeutung der endoskopischen und histologischen Bewertung bei der Behandlung der durch Immun-Checkpoint-Inhibitoren induzierten Kolitis

Abu‐Sbeih et al. (Tue,) haben diese Frage untersucht.

www.synapsesocial.com/papers/69d94a919a6164e50fa3c789 — DOI: https://doi.org/10.1186/s40425-018-0411-1

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial· 2008 · 1,236 citations
2. 14 POST-HOC ANALYSIS OF TOFACITINIB CROHN’S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION· 2018 · 11 citations
3. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)· 2017 · 872 citations
4. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease· 2010 · 3,097 citations
5. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma· 2010 · 15,098 citations